Appili Therapeutics Inc. (APLI.TO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Donald D. Cilla Jr., M.B.A., Pharmd | CEO, President & Director | 588.6k | -- | -- |
| Mr. Kenneth G. Howling | Chief Financial Officer | 481.94k | -- | -- |
| Dr. Gary S. Nabors Ph.D. | Chief Development Officer | 540.01k | -- | -- |
| Dr. Carl Gelhaus Ph.D. | Director of Non-Clinical Research | 296.66k | -- | -- |
| Mr. Arthur Baran | Director of New Product Development | 308.7k | -- | -- |
Appili Therapeutics Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Corporate Governance
Upcoming Events
November 11, 2024 at 10:59 AM UTC - November 15, 2024 at 12:00 PM UTC
Appili Therapeutics Inc. Earnings Date
Recent Events
Recent Events Information Not Available